Alpha Genesis Inc.

Alpha Genesis Inc., a for-profit Subchapter S corporation based in Yemassee, South Carolina, supplies nonhuman primates and breeding colony management services to the federal government as a prime contractor (99% of recent awards), competing predominantly under full-and-open and small-business set-aside designations.

The company operates in a specialized niche within federal biomedical research: acquisition, breeding, care, testing, transportation, and housing of specific pathogen-free nonhuman primates — primarily macaques, cynomolgus monkeys, and African green monkeys — to support infectious disease, immunology, vaccine development, and other NIH research programs. Alpha Genesis maintains government-owned breeding colonies at its primary facility in Yemassee, South Carolina, and subordinate operations in North Bethesda, Maryland and Rockville, Maryland. The company is heavily concentrated in NIH customer relationships and competes on open vehicles rather than set-asides; it earned a single Total Small Business set-aside designation on a recent $8.5 million NIAID delivery order (September 2026), but the vast majority of its portfolio carries no set-aside.

Customer concentration is extreme. The top two funding agencies account for 97% of combined potential value: the National Institute of Allergy and Infectious Diseases ($242 million across 25 awards) and the NIH Office of Logistics and Acquisition Operations ($111.1 million across 139 awards). The two rankings diverge meaningfully — OLAO places many small orders (per diem and testing for individual colonies), while NIAID anchors most of the dollars through breeding-colony maintenance and supply contracts. The Department of the Army Medical Command ($35 million across 12 awards) is a distant third customer. Alpha Genesis has worked with 20 distinct federal agencies, but NIAID, OLAO, and Army Medical Command dominate the footprint.

The vendor holds two marquee parent vehicles. The primary vehicle is NIH OLAO Indefinite Delivery Contract 75N98021D00017, a multi-award IDIQ valued at $33.4 million, against which Alpha Genesis has placed 83 task orders totaling $27.7 million. The second is a $48 million single-award IDIQ with NIAID (awarded September 2024, running through September 2031) for SPF macaque breeding colonies, on which two delivery orders have been issued to date: $8.05 million (September 2025 completion) and $221,664 (September 2031 completion). Legacy vehicles include Non-Human Primates 2016–2021 (57 task orders, $6.4 million) and Non-Human Primates 2010–2016 (18 task orders, $3.9 million). Named representative work includes a $22.8 million cost-plus-fixed-fee definitive contract with NIAID (awarded March 2023, through September 2028) to breed and maintain approximately 3,000 free-ranging rhesus monkeys on Morgan Island, South Carolina; a $8.4 million delivery order for SPF macaque breeding-colony care and provision under the NIAID IDIQ; per diem, testing, and transportation deliveries for NCI, NIMH, NHLBI, and VRC colonies ranging from $30 thousand to $1.38 million per task order; and specific-animal procurement (cynomolgus and African green monkeys, SPF, defined by age and gender specifications) valued from $18 thousand to $816 thousand per delivery.

Activity has declined year over year. Awards per year dropped from 26 in 2022 to 3 in 2026 (through September 30). This decline reflects the portfolio's structure: large, multi-year IDIQ ceiling values anchor the footprint, but task-order issuance against those vehicles has slowed considerably. Eight awards totaling $34.6 million in combined potential value reach ultimate completion within the next twenty-four months, creating recompete exposure for the vendor and recompete opportunity for competitors, particularly on the $22.8 million Morgan Island rhesus-colony contract (the incumbent, Charles River Laboratories, was displaced by Alpha Genesis in the 2023 recompete).

Across SCI-reportable federal service contracts, Alpha Genesis invoiced $47.5 million from FY2022 through FY2024 (the most recent full year in the source). The company operated at 47.9 FTEs in FY2022, declined to 27.6 FTEs in FY2023, then scaled sharply to 118 FTEs in FY2024 — tracking the large $30.3 million invoicing volume that year, driven primarily by the Morgan Island rhesus-colony maintenance contract. Government-paid hourly rates on SCI records range from $81/hr at the tenth percentile to $453/hr at the ninety-fifth percentile, with a median of $100/hr, reflecting the labor mix of animal-care technicians, veterinarians, and research support staff. Across SCI-reportable prime contracts, the vendor self-performed all reported labor with zero subcontractor hours, indicating a vertically integrated delivery model for federally funded work.

The vendor subcontracts to Takeda Vaccines Inc. on vaccine-development and immunogenicity studies, providing transport, per diem, and rhesus macaques for zika-vaccine research (sub awards in February 2023 and May 2022, extension-only modifications with no incremental dollars). This subcontract footprint is minimal — three sub awards total, accounting for 1% of the recent award portfolio — and functions as a specialty supplier role rather than a core business driver. Alpha Genesis' posture is prime-heavy and operationally self-contained.